Pall biotech products have played key development and manufacturing roles in life saving drugs that range from COVID-19 vaccines to cancer-curing monoclonal antibodies. Cutting-edge research demands high quality products that combine industry-leading effectiveness with high performance to increase profitability without sacrificing safety.
We will continue to evolve as the biotech market changes. The rise of single-use facilities, process intensification, integrated unit operations, and continuous processing is improving facility efficiency and flexibility while simultaneously reducing footprint and processing times. Pall has the only bioprocessing portfolio on the market that can support biotech manufacturers from upstream to downstream and into the final filling and finish phases. This single use, multiple solutions, outlook is an end-to-end solution for biotech manufacturers seeking fully validated solutions and guaranteed scalable supply chain security.
With 59.4% of manufactured biopharmaceuticals now shipped in a frozen state, freezing drug substance for storage and transport is becoming ever more important.
Pall Freeze & Go Solutions provide a complete, end-to-end solution to the challenges of filling, freezing, transporting and thawing highly-valuable bulk drug substances, protecting their integrity and preventing biocontainer bag leakages from mechanical damage due to manual handling, and minimizing product loss due to uncontrolled freezing.
The Allegro Connect buffer management system provides buffer on demand. It is a flexible system designed for pilot scale, clinical batches and commercial production to ensure that the right buffer is delivered at the right time, providing an efficient, streamlined workflow. The modular system design enables up to six high volume process buffers to be supplied as required, one at a time, directly to the batch unit operation.
20 Walkup Drive
Westborough, MA 01581
+1 (516) 484-3600
Antibody Therapies: Tackling New FrontiersCell-Based Therapies: The Future of Regenerative MedicineNext in Sequence? Nucleic-Acid-Based Therapies: Current State and Future Promise